Aaron Sato
Chief Tech/Sci/R&D Officer chez TWIST BIOSCIENCE CORPORATION
Profil
Actuellement, Aaron K. Sato est directeur scientifique de Twist Bioscience Corp. Au cours de sa carrière antérieure, il a été vice-président de la recherche chez Sutro Biopharma, Inc, directeur scientifique de LakePharma, Inc, vice-président des sciences des protéines chez Surrozen, Inc, directeur de l'ingénierie des anticorps chez OncoMed Pharmaceuticals, Inc et directeur principal de la découverte chez Dyax Corp. Aaron K. Sato a obtenu un doctorat au Massachusetts Institute of Technology et un diplôme de premier cycle à l'université de Puget Sound.
Postes actifs de Aaron Sato
| Sociétés | Poste | Début |
|---|---|---|
| TWIST BIOSCIENCE CORPORATION | Chief Tech/Sci/R&D Officer | - |
Anciens postes connus de Aaron Sato
| Sociétés | Poste | Fin |
|---|---|---|
LakePharma, Inc.
 LakePharma, Inc. Pharmaceuticals: MajorHealth Technology LakePharma, Inc. operates as a contract research organization which engages in the provision of antibody and protein engineering, cell line development, and protein production. Its services include antibody generation, antibody engineering and production, protein engineering and production, protein conjugation, protein analytics, bioassays, DNA studio, stable cell lines, bio manufacturing and service packages. The company was founded by Hua Tu in September 2009 and is headquartered in Belmont, CA. | Chief Tech/Sci/R&D Officer | 01/06/2018 |
| SUTRO BIOPHARMA, INC. | Chief Tech/Sci/R&D Officer | 01/01/2017 |
Surrozen Operating, Inc.
 Surrozen Operating, Inc. BiotechnologyHealth Technology Surrozen Operating, Inc. operates as a biopharmaceutical company that focuses on harnessing the Wnt pathway for applications in regenerative medicine. The firm implements a surrogate Wnt platform with the potential to unlock stem cell control in an array of human tissues. The company was founded by K. Christopher Garcia, Roeland Nusse, Calvin J. Kuo, Hans Claudia and Claudia Janda in 2015 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 01/01/2017 |
| ONCOMED PHARMACEUTICALS INC | Corporate Officer/Principal | 01/07/2012 |
| DYAX CORP. | Corporate Officer/Principal | 01/07/2006 |
Formation de Aaron Sato
| Massachusetts Institute of Technology | Doctorate Degree |
| University of Puget Sound | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| SUTRO BIOPHARMA, INC. | Health Technology |
| TWIST BIOSCIENCE CORPORATION | Health Technology |
| Entreprise privées | 4 |
|---|---|
Dyax Corp.
 Dyax Corp. Pharmaceuticals: MajorHealth Technology Dyax Corp. engages in discovery, development and commercialization of novel biotherapeutics. The company was founded by Henry E. Blair in 1989 and is headquartered in Burlington, MA. | Health Technology |
OncoMed Pharmaceuticals, Inc.
 OncoMed Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoMed Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which focuses on discovering and developing novel therapeutics for cancer's growth, resistance, recurrence and metastasis. The company was founded by Michael F. Clarke and Max Wicha in August 2004 and is headquartered in Redwood City, CA. | Health Technology |
LakePharma, Inc.
LakePharma, Inc. Pharmaceuticals: MajorHealth Technology LakePharma, Inc. operates as a contract research organization which engages in the provision of antibody and protein engineering, cell line development, and protein production. Its services include antibody generation, antibody engineering and production, protein engineering and production, protein conjugation, protein analytics, bioassays, DNA studio, stable cell lines, bio manufacturing and service packages. The company was founded by Hua Tu in September 2009 and is headquartered in Belmont, CA. | Health Technology |
Surrozen Operating, Inc.
Surrozen Operating, Inc. BiotechnologyHealth Technology Surrozen Operating, Inc. operates as a biopharmaceutical company that focuses on harnessing the Wnt pathway for applications in regenerative medicine. The firm implements a surrogate Wnt platform with the potential to unlock stem cell control in an array of human tissues. The company was founded by K. Christopher Garcia, Roeland Nusse, Calvin J. Kuo, Hans Claudia and Claudia Janda in 2015 and is headquartered in South San Francisco, CA. | Health Technology |
